Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 141 articles:
HTML format
Text format



Single Articles


    February 2018
  1. ZHU Y, Wang PP, Zhai G, Bapat B, et al
    Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake.
    BMC Cancer. 2018;18:155.
    PubMed     Text format     Abstract available


  2. RICHTER J, Kretz AL, Lemke J, Fauler M, et al
    CK1alpha overexpression correlates with poor survival in colorectal cancer.
    BMC Cancer. 2018;18:140.
    PubMed     Text format     Abstract available


  3. KLAUCK PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, et al
    Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
    BMC Cancer. 2018;18:136.
    PubMed     Text format     Abstract available


    January 2018
  4. BATTAGLIN F, Schirripa M, Buggin F, Pietrantonio F, et al
    The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
    BMC Cancer. 2018;18:98.
    PubMed     Text format     Abstract available


  5. ENGSTRAND J, Nilsson H, Stromberg C, Jonas E, et al
    Colorectal cancer liver metastases - a population-based study on incidence, management and survival.
    BMC Cancer. 2018;18:78.
    PubMed     Text format     Abstract available


  6. WANG X, Chen J, Wang J, Yu F, et al
    Correction to: Metalloproteases meprin-a (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer.
    BMC Cancer. 2018;18:70.
    PubMed     Text format     Abstract available


  7. SHAW E, Farris MS, Stone CR, Derksen JWG, et al
    Effects of physical activity on colorectal cancer risk among family history and body mass index subgroups: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:71.
    PubMed     Text format     Abstract available


  8. KONG X, Li J, Cai Y, Tian Y, et al
    A modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database.
    BMC Cancer. 2018;18:50.
    PubMed     Text format     Abstract available


  9. DAVIS MM, Freeman M, Shannon J, Coronado GD, et al
    A systematic review of clinic and community intervention to increase fecal testing for colorectal cancer in rural and low-income populations in the United States - How, what and when?
    BMC Cancer. 2018;18:40.
    PubMed     Text format     Abstract available


  10. GU MJ, Huang QC, Bao CZ, Li YJ, et al
    Attributable causes of colorectal cancer in China.
    BMC Cancer. 2018;18:38.
    PubMed     Text format     Abstract available


  11. FARSHIDFAR F, Kopciuk KA, Hilsden R, McGregor SE, et al
    A quantitative multimodal metabolomic assay for colorectal cancer.
    BMC Cancer. 2018;18:26.
    PubMed     Text format     Abstract available


    December 2017
  12. ZHANG K, Wang Y, Yu X, Shi Y, et al
    Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.
    BMC Cancer. 2017;17:899.
    PubMed     Text format     Abstract available


  13. FALKOWSKI S, Woillard JB, Postil D, Tubiana-Mathieu N, et al
    Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study.
    BMC Cancer. 2017;17:901.
    PubMed     Text format     Abstract available


  14. SONG N, Shin A, Jung HS, Oh JH, et al
    Effects of interactions between common genetic variants and smoking on colorectal cancer.
    BMC Cancer. 2017;17:869.
    PubMed     Text format     Abstract available


  15. SHIN HY, Suh M, Park B, Jun JK, et al
    Perceptions of colorectal cancer screening and recommendation behaviors among physicians in Korea.
    BMC Cancer. 2017;17:860.
    PubMed     Text format     Abstract available


  16. YEH YS, Chang YT, Ma CJ, Huang CW, et al
    First-decade patient with colorectal cancer carrying both germline and somatic mutations in APC gene.
    BMC Cancer. 2017;17:849.
    PubMed     Text format     Abstract available


  17. CAO B, Luo L, Feng L, Ma S, et al
    A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    BMC Cancer. 2017;17:844.
    PubMed     Text format     Abstract available


  18. BEEBE-DIMMER JL, Yee C, Paskett E, Schwartz AG, et al
    Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative.
    BMC Cancer. 2017;17:848.
    PubMed     Text format     Abstract available


  19. LEE J, Xiao YY, Sun YY, Balderacchi J, et al
    Prevalence and characteristics of hereditary non-polyposis colorectal cancer (HNPCC) syndrome in immigrant Asian colorectal cancer patients.
    BMC Cancer. 2017;17:843.
    PubMed     Text format     Abstract available


  20. VULCAN A, Manjer J, Ohlsson B
    High blood glucose levels are associated with higher risk of colon cancer in men: a cohort study.
    BMC Cancer. 2017;17:842.
    PubMed     Text format     Abstract available


  21. COELHO H, Jones-Hughes T, Snowsill T, Briscoe S, et al
    A systematic review of test accuracy studies evaluating molecular micro-satellite instability testing for the detection of individuals with lynch syndrome.
    BMC Cancer. 2017;17:836.
    PubMed     Text format     Abstract available


  22. BENEDICTO A, Marquez J, Herrero A, Olaso E, et al
    Decreased expression of the beta2 integrin on tumor cells is associated with a reduction in liver metastasis of colorectal cancer in mice.
    BMC Cancer. 2017;17:827.
    PubMed     Text format     Abstract available


  23. ZHOU P, Wang C, Hu Z, Chen W, et al
    Genistein induces apoptosis of colon cancer cells by reversal of epithelial-to-mesenchymal via a Notch1/NF-kappaB/slug/E-cadherin pathway.
    BMC Cancer. 2017;17:813.
    PubMed     Text format     Abstract available


    November 2017
  24. HAN VAN KRIEKEN J, Kafatos G, Bennett J, Mineur L, et al
    Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
    BMC Cancer. 2017;17:798.
    PubMed     Text format     Abstract available


  25. YANG J, Du XL, Li S, Wu Y, et al
    The risk and survival outcome of subsequent primary colorectal cancer after the first primary colorectal cancer: cases from 1973 to 2012.
    BMC Cancer. 2017;17:783.
    PubMed     Text format     Abstract available


  26. THIEBAULT Q, Defossez G, Karayan-Tapon L, Ingrand P, et al
    Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.
    BMC Cancer. 2017;17:765.
    PubMed     Text format     Abstract available


  27. STEVANATO FILHO PR, Aguiar Junior S, Begnami MD, Kuasne H, et al
    Oestrogen receptor beta isoform expression in sporadic colorectal cancer, familial adenomatous polyposis and progressive stages of colorectal cancer.
    BMC Cancer. 2017;17:754.
    PubMed     Text format     Abstract available


  28. SONG Y, Yang Y, Gao P, Chen X, et al
    The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer.
    BMC Cancer. 2017;17:744.
    PubMed     Text format     Abstract available


  29. ALONSO-MOLERO J, Gonzalez-Donquiles C, Fernandez-Villa T, de Souza-Teixeira F, et al
    Alterations in PGC1alpha expression levels are involved in colorectal cancer risk: a qualitative systematic review.
    BMC Cancer. 2017;17:731.
    PubMed     Text format     Abstract available


  30. TAKAHASHI H, Takahashi M, Ohnuma S, Unno M, et al
    microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.
    BMC Cancer. 2017;17:723.
    PubMed     Text format     Abstract available


  31. YANG C, Zou K, Zheng L, Xiong B, et al
    Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    BMC Cancer. 2017;17:725.
    PubMed     Text format     Abstract available


  32. YU X, Mi L, Dong J, Zou J, et al
    Long intergenic non-protein-coding RNA 1567 (LINC01567) acts as a "sponge" against microRNA-93 in regulating the proliferation and tumorigenesis of human colon cancer stem cells.
    BMC Cancer. 2017;17:716.
    PubMed     Text format     Abstract available


    October 2017
  33. STEVENS JR, Herrick JS, Wolff RK, Slattery ML, et al
    Identifying factors associated with the direction and significance of microRNA tumor-normal expression differences in colorectal cancer.
    BMC Cancer. 2017;17:707.
    PubMed     Text format     Abstract available


  34. RATJEN I, Schafmayer C, di Giuseppe R, Waniek S, et al
    Postdiagnostic physical activity, sleep duration, and TV watching and all-cause mortality among long-term colorectal cancer survivors: a prospective cohort study.
    BMC Cancer. 2017;17:701.
    PubMed     Text format     Abstract available


  35. UNGARI AQ, Pereira LRL, Nunes AA, Peria FM, et al
    Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
    BMC Cancer. 2017;17:691.
    PubMed     Text format     Abstract available


    September 2017
  36. GARCIA RODRIGUEZ LA, Soriano-Gabarro M, Bromley S, Lanas A, et al
    New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice.
    BMC Cancer. 2017;17:637.
    PubMed     Text format     Abstract available


  37. BALTRUSKEVICIENE E, Schveigert D, Stankevicius V, Mickys U, et al
    Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding.
    BMC Cancer. 2017;17:607.
    PubMed     Text format     Abstract available


    August 2017
  38. LIU Z, Qi L, Li Y, Zhao X, et al
    VEGFR2 regulates endothelial differentiation of colon cancer cells.
    BMC Cancer. 2017;17:593.
    PubMed     Text format     Abstract available


  39. ARANA-ARRI E, Idigoras I, Uranga B, Perez R, et al
    Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
    BMC Cancer. 2017;17:577.
    PubMed     Text format     Abstract available


  40. AYKUT B, Ochs M, Radhakrishnan P, Brill A, et al
    EMX2 gene expression predicts liver metastasis and survival in colorectal cancer.
    BMC Cancer. 2017;17:555.
    PubMed     Text format     Abstract available


  41. WINTHER SB, Osterlund P, Berglund A, Glimelius B, et al
    Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    BMC Cancer. 2017;17:548.
    PubMed     Text format     Abstract available


  42. GUIRIGUET C, Pera G, Castells A, Toran P, et al
    Impact of comorbid conditions on participation in an organised colorectal cancer screening programme: a cross-sectional study.
    BMC Cancer. 2017;17:524.
    PubMed     Text format     Abstract available


    July 2017
  43. WU Z, Qin G, Zhao N, Jia H, et al
    Assessing the adequacy of lymph node yield for different tumor stages of colon cancer by nodal staging scores.
    BMC Cancer. 2017;17:498.
    PubMed     Text format     Abstract available


    June 2017
  44. LUND CM, Vistisen KK, Dehlendorff C, Ronholt F, et al
    The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).
    BMC Cancer. 2017;17:448.
    PubMed     Text format     Abstract available


  45. GOLSTEIJN RHJ, Bolman C, Volders E, Peels DA, et al
    Development of a computer-tailored physical activity intervention for prostate and colorectal cancer patients and survivors: OncoActive.
    BMC Cancer. 2017;17:446.
    PubMed     Text format     Abstract available


  46. LIU D, Li J, Gao J, Li Y, et al
    Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    BMC Cancer. 2017;17:437.
    PubMed     Text format     Abstract available


  47. RIEDL JM, Posch F, Bezan A, Szkandera J, et al
    Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.
    BMC Cancer. 2017;17:415.
    PubMed     Text format     Abstract available


  48. CREMOLINI C, Marmorino F, Loupakis F, Masi G, et al
    TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
    BMC Cancer. 2017;17:408.
    PubMed     Text format     Abstract available


  49. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
    The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study.
    BMC Cancer. 2017;17:404.
    PubMed     Text format     Abstract available


  50. WON DD, Lee JI, Lee IK, Oh ST, et al
    The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
    BMC Cancer. 2017;17:403.
    PubMed     Text format     Abstract available


    May 2017
  51. BOCUK D, Wolff A, Krause P, Salinas G, et al
    The adaptation of colorectal cancer cells when forming metastases in the liver: expression of associated genes and pathways in a mouse model.
    BMC Cancer. 2017;17:342.
    PubMed     Text format     Abstract available


  52. MAGAJI BA, Moy FM, Roslani AC, Law CW, et al
    Survival rates and predictors of survival among colorectal cancer patients in a Malaysian tertiary hospital.
    BMC Cancer. 2017;17:339.
    PubMed     Text format     Abstract available


  53. LAMKADDEM M, Elferink MAG, Seeleman MC, Dekker E, et al
    Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study.
    BMC Cancer. 2017;17:312.
    PubMed     Text format     Abstract available


  54. KONDO Y, Hayashi K, Kawakami K, Miwa Y, et al
    KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.
    BMC Cancer. 2017;17:311.
    PubMed     Text format     Abstract available


  55. XIE M, Qin H, Luo Q, Huang Q, et al
    MicroRNA-30a regulates cell proliferation and tumor growth of colorectal cancer by targeting CD73.
    BMC Cancer. 2017;17:305.
    PubMed     Text format     Abstract available


  56. TAYLOR SA, Mallett S, Miles A, Beare S, et al
    Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
    BMC Cancer. 2017;17:299.
    PubMed     Text format     Abstract available


    April 2017
  57. JUNG SY, Sobel EM, Papp JC, Zhang ZF, et al
    Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women.
    BMC Cancer. 2017;17:290.
    PubMed     Text format     Abstract available


  58. UBINK I, Bloemendal HJ, Elias SG, Brink MA, et al
    Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).
    BMC Cancer. 2017;17:282.
    PubMed     Text format     Abstract available


  59. LELONG B, de Chaisemartin C, Meillat H, Cournier S, et al
    A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design.
    BMC Cancer. 2017;17:253.
    PubMed     Text format     Abstract available


  60. BRUNGS D, Aghmesheh M, de Souza P, Ng W, et al
    Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients.
    BMC Cancer. 2017;17:251.
    PubMed     Text format     Abstract available


  61. CHEN XL, Chen ZQ, Zhu SL, Liu TW, et al
    Prognostic value of transforming growth factor-beta in patients with colorectal cancer who undergo surgery: a meta-analysis.
    BMC Cancer. 2017;17:240.
    PubMed     Text format     Abstract available


  62. CHEN Y, Wang Y, Shi Y, Dai G, et al
    Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients.
    BMC Cancer. 2017;17:242.
    PubMed     Text format     Abstract available


  63. NAKAYAMA G, Ishigure K, Yokoyama H, Uehara K, et al
    The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
    BMC Cancer. 2017;17:243.
    PubMed     Text format     Abstract available


    March 2017
  64. MCINNES T, Zou D, Rao DS, Munro FM, et al
    Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
    BMC Cancer. 2017;17:228.
    PubMed     Text format     Abstract available


  65. LI X, Lu H, Xu K, Wang H, et al
    Negative lymph node count is an independent prognostic factor for patients with rectal cancer who received preoperative radiotherapy.
    BMC Cancer. 2017;17:227.
    PubMed     Text format     Abstract available


  66. LERECLUS E, Tout M, Girault A, Baroukh N, et al
    A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
    BMC Cancer. 2017;17:220.
    PubMed     Text format     Abstract available


  67. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Text format     Abstract available


  68. CERVANTES-MADRID D, Wettergren Y, Falk P, Lundholm K, et al
    DNA alterations in Cd133+ and Cd133- tumour cells enriched from intra-operative human colon tumour biopsies.
    BMC Cancer. 2017;17:219.
    PubMed     Text format     Abstract available


  69. DE LA MARE JA, Jurgens T, Edkins AL
    Extracellular Hsp90 and TGFbeta regulate adhesion, migration and anchorage independent growth in a paired colon cancer cell line model.
    BMC Cancer. 2017;17:202.
    PubMed     Text format     Abstract available


  70. FENG YR, Jin J, Ren H, Wang X, et al
    Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
    BMC Cancer. 2017;17:182.
    PubMed     Text format     Abstract available


    February 2017
  71. TSUJII Y, Hayashi Y, Maekawa A, Fujinaga T, et al
    Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: a case report.
    BMC Cancer. 2017;17:152.
    PubMed     Text format     Abstract available


  72. SINGH VP, Katta S, Kumar S
    WD-repeat protein WDR13 is a novel transcriptional regulator of c-Jun and modulates intestinal homeostasis in mice.
    BMC Cancer. 2017;17:148.
    PubMed     Text format     Abstract available


  73. HE Z, Yu L, Luo S, Li M, et al
    miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4.
    BMC Cancer. 2017;17:140.
    PubMed     Text format     Abstract available


  74. MA J, Yang QL, Ling Y
    Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
    BMC Cancer. 2017;17:132.
    PubMed     Text format     Abstract available


  75. PAHLE J, Menzel L, Niesler N, Kobelt D, et al
    Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy.
    BMC Cancer. 2017;17:129.
    PubMed     Text format     Abstract available


  76. RIGTER LS, Spaander MC, Moons LM, Bisseling TM, et al
    Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.
    BMC Cancer. 2017;17:112.
    PubMed     Text format     Abstract available


  77. CAREY M, Sanson-Fisher R, Macrae F, Cameron E, et al
    Improving adherence to colorectal cancer surveillance guidelines: results of a randomised controlled trial.
    BMC Cancer. 2017;17:106.
    PubMed     Text format     Abstract available


  78. IRELAND MJ, March S, Crawford-Williams F, Cassimatis M, et al
    A systematic review of geographical differences in management and outcomes for colorectal cancer in Australia.
    BMC Cancer. 2017;17:95.
    PubMed     Text format     Abstract available


  79. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Text format     Abstract available


    January 2017
  80. HENRIKSEN HB, Raeder H, Bohn SK, Paur I, et al
    The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: a food-based multicentre randomized controlled trial.
    BMC Cancer. 2017;17:83.
    PubMed     Text format     Abstract available


  81. LI Q, Li Y, Dai W, Wang S, et al
    Adjuvant radiotherapy improves cause specific survival in stage II, not stage III mucinous carcinoma of the rectum.
    BMC Cancer. 2017;17:80.
    PubMed     Text format     Abstract available


  82. VAN ZUTPHEN M, Winkels RM, van Duijnhoven FJ, van Harten-Gerritsen SA, et al
    An increase in physical activity after colorectal cancer surgery is associated with improved recovery of physical functioning: a prospective cohort study.
    BMC Cancer. 2017;17:74.
    PubMed     Text format     Abstract available


  83. HINZ S, Hendricks A, Wittig A, Schafmayer C, et al
    Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
    BMC Cancer. 2017;17:53.
    PubMed     Text format     Abstract available


  84. QIU P, Wang S, Liu M, Ma H, et al
    Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells.
    BMC Cancer. 2017;17:55.
    PubMed     Text format     Abstract available


  85. PALSHOF JA, Hogdall EV, Poulsen TS, Linnemann D, et al
    Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
    BMC Cancer. 2017;17:48.
    PubMed     Text format     Abstract available


  86. NAKAYAMA I, Shinozaki E, Matsushima T, Wakatsuki T, et al
    Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    BMC Cancer. 2017;17:38.
    PubMed     Text format     Abstract available


  87. KURODA K, Fukuda T, Krstic-Demonacos M, Demonacos C, et al
    miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway.
    BMC Cancer. 2017;17:33.
    PubMed     Text format     Abstract available


  88. STEVENSON HL, Prats MM, Sasatomi E
    Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    BMC Cancer. 2017;17:35.
    PubMed     Text format     Abstract available


  89. NAING C, Aung K, Lai PK, Mak JW, et al
    Association between telomere length and the risk of colorectal cancer: a meta-analysis of observational studies.
    BMC Cancer. 2017;17:24.
    PubMed     Text format     Abstract available


  90. AL-KHAYAL K, Alafeefy A, Vaali-Mohammed MA, Mahmood A, et al
    Novel derivative of aminobenzenesulfonamide (3c) induces apoptosis in colorectal cancer cells through ROS generation and inhibits cell migration.
    BMC Cancer. 2017;17:4.
    PubMed     Text format     Abstract available


    December 2016
  91. YEDID N, Kalma Y, Malcov M, Amit A, et al
    The effect of a germline mutation in the APC gene on beta-catenin in human embryonic stem cells.
    BMC Cancer. 2016;16:952.
    PubMed     Text format     Abstract available


  92. MODARAI SR, Opdenaker LM, Viswanathan V, Fields JZ, et al
    Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells.
    BMC Cancer. 2016;16:941.
    PubMed     Text format     Abstract available


    November 2016
  93. ZHANG J, Ren J, Wei J, Chong CC, et al
    Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma.
    BMC Cancer. 2016;16:926.
    PubMed     Text format     Abstract available


  94. KLOSE J, Eissele J, Volz C, Schmitt S, et al
    Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/beta-catenin signaling in CD133+ human colorectal cancer cells.
    BMC Cancer. 2016;16:896.
    PubMed     Text format     Abstract available


  95. PAWLAK A, Ziolo E, Fiedorowicz A, Fidyt K, et al
    Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.
    BMC Cancer. 2016;16:893.
    PubMed     Text format     Abstract available


  96. MEERSON A, Yehuda H
    Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells.
    BMC Cancer. 2016;16:882.
    PubMed     Text format     Abstract available


  97. REFAAT B, El-Shemi AG, Mohamed AM, Kensara OA, et al
    Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.
    BMC Cancer. 2016;16:879.
    PubMed     Text format     Abstract available


  98. ZHOU L, Yu L, Zhu B, Wu S, et al
    Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.
    BMC Cancer. 2016;16:876.
    PubMed     Text format     Abstract available


  99. STEPPELER C, Sodring M, Paulsen JE
    Colorectal Carcinogenesis in the A/J Min/+ Mouse Model is Inhibited by Hemin, Independently of Dietary Fat Content and Fecal Lipid Peroxidation Rate.
    BMC Cancer. 2016;16:832.
    PubMed     Text format     Abstract available


    October 2016
  100. BOLEIJ A, Tack V, Taylor A, Kafatos G, et al
    RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.
    BMC Cancer. 2016;16:825.
    PubMed     Text format     Abstract available


  101. XU C, Zhou D, Pan F, Liu Y, et al
    A novel variant on chromosome 6p21.1 is associated with the risk of developing colorectal cancer: a two-stage case-control study in Han Chinese.
    BMC Cancer. 2016;16:807.
    PubMed     Text format     Abstract available


  102. DING C, Li L, Yang T, Fan X, et al
    Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    BMC Cancer. 2016;16:791.
    PubMed     Text format     Abstract available


  103. FORREST CM, McNair K, Vincenten MC, Darlington LG, et al
    Selective depletion of tumour suppressors Deleted in Colorectal Cancer (DCC) and neogenin by environmental and endogenous serine proteases: linking diet and cancer.
    BMC Cancer. 2016;16:772.
    PubMed     Text format     Abstract available


  104. MYERS RE, Wolf T, Shwae P, Hegarty S, et al
    A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients.
    BMC Cancer. 2016;16:766.
    PubMed     Text format     Abstract available


    January 2016
  105. DUTTA D, Chakraborty B, Sarkar A, Chowdhury C, et al
    A potent betulinic acid analogue ascertains an antagonistic mechanism between autophagy and proteasomal degradation pathway in HT-29 cells.
    BMC Cancer. 2016;16:23.
    PubMed     Text format     Abstract available


  106. DIAO D, Wang L, Wan J, Chen Z, et al
    MEK5 overexpression is associated with the occurrence and development of colorectal cancer.
    BMC Cancer. 2016;16:302.
    PubMed     Text format     Abstract available


  107. CHEN KH, Shao YY, Chen HM, Lin YL, et al
    Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    BMC Cancer. 2016;16:327.
    PubMed     Text format     Abstract available


  108. SEGELOV E, Waring P, Desai J, Wilson K, et al
    ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
    BMC Cancer. 2016;16:339.
    PubMed     Text format     Abstract available


  109. KURAMOCHI H, Nakamura A, Nakajima G, Kaneko Y, et al
    PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study.
    BMC Cancer. 2016;16:366.
    PubMed     Text format     Abstract available


  110. PARK WC, Kim HR, Kang DB, Ryu JS, et al
    Comparative expression patterns and diagnostic efficacies of SR splicing factors and HNRNPA1 in gastric and colorectal cancer.
    BMC Cancer. 2016;16:358.
    PubMed     Text format     Abstract available


  111. GOVINDARAJAN R, Posey J, Chao CY, Lu R, et al
    A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer.
    BMC Cancer. 2016;16:368.
    PubMed     Text format     Abstract available


  112. QUINTANA JM, Gonzalez N, Anton-Ladislao A, Redondo M, et al
    Colorectal cancer health services research study protocol: the CCR-CARESS observational prospective cohort project.
    BMC Cancer. 2016;16:435.
    PubMed     Text format     Abstract available


  113. ADENIS A, de la Fouchardiere C, Paule B, Burtin P, et al
    Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program.
    BMC Cancer. 2016;16:412.
    PubMed     Text format     Abstract available


  114. ALLARY C, Bourmaud A, Tinquaut F, Oriol M, et al
    ColoNav: patient navigation for colorectal cancer screening in deprived areas - Study protocol.
    BMC Cancer. 2016;16:416.
    PubMed     Text format     Abstract available


  115. BELLAMKONDA K, Chandrashekar NK, Osman J, Selvanesan BC, et al
    The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model.
    BMC Cancer. 2016;16:425.
    PubMed     Text format     Abstract available


  116. LAAKE I, Larsen IK, Selmer R, Thune I, et al
    Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study.
    BMC Cancer. 2016;16:402.
    PubMed     Text format     Abstract available


  117. WANG X, Chen J, Wang J, Yu F, et al
    Metalloproteases meprin-a (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer.
    BMC Cancer. 2016;16:383.
    PubMed     Text format     Abstract available


  118. PETRELLI F, Barni S, Bertocchi P, Zaniboni A, et al
    TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
    BMC Cancer. 2016;16:386.
    PubMed     Text format     Abstract available


  119. LI WM, Hu TT, Zhou LL, Feng YM, et al
    Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
    BMC Cancer. 2016;16:454.
    PubMed     Text format     Abstract available


  120. KLUPP F, Neumann L, Kahlert C, Diers J, et al
    Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients.
    BMC Cancer. 2016;16:494.
    PubMed     Text format     Abstract available


  121. KASI PM, Kotani D, Cecchini M, Shitara K, et al
    Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
    BMC Cancer. 2016;16:467.
    PubMed     Text format     Abstract available


  122. CHU QD, Zhou M, Medeiros KL, Peddi P, et al
    Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy.
    BMC Cancer. 2016;16:460.
    PubMed     Text format     Abstract available


  123. LUNDBERG IV, Edin S, Eklof V, Oberg A, et al
    SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    BMC Cancer. 2016;16:471.
    PubMed     Text format     Abstract available


  124. WARSCHKOW R, Sulz MC, Marti L, Tarantino I, et al
    Better survival in right-sided versus left-sided stage I - III colon cancer patients.
    BMC Cancer. 2016;16:554.
    PubMed     Text format     Abstract available


  125. MARTINS SF, Amorim R, Viana-Pereira M, Pinheiro C, et al
    Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis.
    BMC Cancer. 2016;16:535.
    PubMed     Text format     Abstract available


  126. ADENIS A, de la Fouchardiere C, Paule B, Burtin P, et al
    Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
    BMC Cancer. 2016;16:518.
    PubMed     Text format    


  127. FREEMAN K, Saunders MP, Uthman OA, Taylor-Phillips S, et al
    Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.
    BMC Cancer. 2016;16:523.
    PubMed     Text format     Abstract available


  128. IKEYA T, Maeda K, Nagahara H, Shibutani M, et al
    The combined expression of Semaphorin4D and PlexinB1 predicts disease recurrence in colorectal cancer.
    BMC Cancer. 2016;16:525.
    PubMed     Text format     Abstract available


  129. DAMM R, Seidensticker R, Ulrich G, Breier L, et al
    Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.
    BMC Cancer. 2016;16:509.
    PubMed     Text format     Abstract available


  130. MACK E, Stabla K, Riera-Knorrenschild J, Moll R, et al
    A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.
    BMC Cancer. 2016;16:585.
    PubMed     Text format     Abstract available


  131. JAGADISH N, Parashar D, Gupta N, Agarwal S, et al
    Heat shock protein 70-2 (HSP70-2) is a novel therapeutic target for colorectal cancer and is associated with tumor growth.
    BMC Cancer. 2016;16:561.
    PubMed     Text format     Abstract available


  132. ANTUNES L, Mendonca D, Bento MJ, Rachet B, et al
    No inequalities in survival from colorectal cancer by education and socioeconomic deprivation - a population-based study in the North Region of Portugal, 2000-2002.
    BMC Cancer. 2016;16:608.
    PubMed     Text format     Abstract available


  133. LI C, Zhao L, Chen Y, He T, et al
    MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression.
    BMC Cancer. 2016;16:605.
    PubMed     Text format     Abstract available


  134. BOTREL TE, Clark LG, Paladini L, Clark OA, et al
    Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.
    BMC Cancer. 2016;16:677.
    PubMed     Text format     Abstract available


  135. ZHANG ZY, Luo QF, Yin XW, Dai ZL, et al
    Nomograms to predict survival after colorectal cancer resection without preoperative therapy.
    BMC Cancer. 2016;16:658.
    PubMed     Text format     Abstract available


  136. PITA-FERNANDEZ S, Gonzalez-Saez L, Lopez-Calvino B, Seoane-Pillado T, et al
    Effect of diagnostic delay on survival in patients with colorectal cancer: a retrospective cohort study.
    BMC Cancer. 2016;16:664.
    PubMed     Text format     Abstract available


  137. LI C, Zhou L, He J, Fang XQ, et al
    Increased long noncoding RNA SNHG20 predicts poor prognosis in colorectal cancer.
    BMC Cancer. 2016;16:655.
    PubMed     Text format     Abstract available


  138. PADHAN N, Nordling TE, Sundstrom M, Akerud P, et al
    High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer.
    BMC Cancer. 2016;16:683.
    PubMed     Text format     Abstract available


  139. PARK JS, Huh JW, Park YA, Cho YB, et al
    Clinically suspected T4 colorectal cancer may be resected using a laparoscopic approach.
    BMC Cancer. 2016;16:714.
    PubMed     Text format     Abstract available


  140. AKINYEMIJU T, Meng Q, Vin-Raviv N
    Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes: analysis of the nationwide inpatient sample.
    BMC Cancer. 2016;16:715.
    PubMed     Text format     Abstract available


  141. LEE KS, Kwak Y, Nam KH, Kim DW, et al
    Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ss-catenin.
    BMC Cancer. 2016;16:730.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: